Cancer's Nemesis: New "Super T-Cells" Shatter Solid Tumor Defenses!
- Scientists have engineered "supercharged" CAR T-cells targeting MUC1*, a protein found on 75% of solid tumors.
- These cells, enhanced with 1XX mutations, show increased persistence and can destroy cancer cells even with low target levels.
- Groundbreaking animal studies suggest this approach could overcome previous barriers in treating solid tumors, offering hope to many.
For three long decades, the MUC1 protein, a marker flaunted by 75% of insidious solid tumors, has taunted researchers—a seemingly perfect target, yet maddeningly out of reach for effective therapies1, 5. Now, the tide may be turning. Minerva Biotechnologies has unveiled a breakthrough in the relentless war against cancer, published in the Journal for ImmunoTherapy of Cancer.
They've zeroed in on MUC1* – a specific, growth-fueling form of MUC17. Their weapon? CAR T-cells, the patient's own immune cells, transformed into precision cancer assassins. But these aren't just any CAR T-cells. Fortified with revolutionary 1XX mutations, these "super-soldiers" fight harder and longer, overcoming the exhaustion that plagues other treatments. Crucially, they hunt down and obliterate cancer cells even those expressing low levels of MUC1*, a common trick tumors use to evade destruction7.
In stringent animal models, these MUC1*-CAR-1XX T-cells not only eradicated tumors but also suppressed their recurrence. "These findings...are very encouraging," stated 1XX inventor Michel Sadelain. This heralds a potential new dawn, suggesting a vast patient population battling diverse solid tumors could finally have a powerful new ally7. Minerva's FDA-approved IND for a MUC1*-CAR22 further underscores this rapid advance. The solid tumor barrier is finally showing cracks.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.